RT Journal Article
SR Electronic
T1 Genome-wide analysis in 756,646 individuals provides first genetic evidence that <em>ACE2</em> expression influences COVID-19 risk and yields genetic risk scores predictive of severe disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.14.20248176
DO 10.1101/2020.12.14.20248176
A1 Horowitz, J. E.
A1 Kosmicki, J. A.
A1 Damask, A.
A1 Sharma, D.
A1 Roberts, G. H. L.
A1 Justice, A. E.
A1 Banerjee, N.
A1 Coignet, M. V.
A1 Yadav, A.
A1 Leader, J. B.
A1 Marcketta, A.
A1 Park, D. S.
A1 Lanche, R.
A1 Maxwell, E.
A1 Knight, S. C.
A1 Bai, X.
A1 Guturu, H.
A1 Sun, D.
A1 Baltzell, A.
A1 Kury, F. S. P.
A1 Backman, J. D.
A1 Girshick, A. R.
A1 O’Dushlaine, C.
A1 McCurdy, S. R.
A1 Partha, R.
A1 Mansfield, A. J.
A1 Turissini, D. A.
A1 Li, A. H.
A1 Zhang, M.
A1 Mbatchou, J.
A1 Watanabe, K.
A1 Gurski, L.
A1 McCarthy, S. E.
A1 Kang, H. M.
A1 Dobbyn, L.
A1 Stahl, E.
A1 Verma, A.
A1 Sirugo, G.
A1 ,
A1 Ritchie, M. D.
A1 Jones, M.
A1 Balasubramanian, S.
A1 Siminovitch, K.
A1 Salerno, W. J.
A1 Shuldiner, A. R.
A1 Rader, D. J.
A1 Mirshahi, T.
A1 Locke, A. E.
A1 Marchini, J.
A1 Overton, J. D.
A1 Carey, D. J.
A1 Habegger, L.
A1 Cantor, M. N.
A1 Rand, K. A.
A1 Hong, E. L.
A1 Reid, J. G.
A1 Ball, C. A.
A1 Baras, A.
A1 Abecasis, G. R.
A1 Ferreira, M. A.
YR 2021
UL http://medrxiv.org/content/early/2021/06/10/2020.12.14.20248176.abstract
AB SARS-CoV-2 enters host cells by binding angiotensin-converting enzyme 2 (ACE2). Through a genome-wide association study, we show that a rare variant (MAF = 0.3%, odds ratio 0.60, P=4.5x10-13) that down-regulates ACE2 expression reduces risk of COVID-19 disease, providing human genetics support for the hypothesis that ACE2 levels influence COVID-19 risk. Further, we show that common genetic variants define a risk score that predicts severe disease among COVID-19 cases.Competing Interest StatementJ.E.H., J.A.K., A.D., D.S., N.B, A.Y., A.M., R.L., E.M., X.B., D.S., F.S.P.K., J.D.B., C.OD., A.J.M., D.A.T., A.H.L., J.M., K.W., L.G., S.E.M, H.M.K., L.D., E.S., M.J., S.B., K.S.M, W.J.S., A.R.S., A.E.L., J.M., J.O., L.H., M.N.C., J.G.R., A.B., G.R.A., and M.A.F. are current employees and/or stockholders of Regeneron Genetics Center or Regeneron Pharmaceuticals. G.H.L.R., M.V.C., D.S.P., S.C.K. A.Bal., A.R.G., S.R.M., R.P., M.Z., K.A.R., E.L.H., C.A.B. are current employees at AncestryDNA and may hold equity in AncestryDNA. The other authors declare no competing interests.Funding StatementThe Penn Medicine BioBank is funded by a gift from the Smilow family, the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA Award Number UL1TR001878, and the Perelman School of Medicine at the University of Pennsylvania. All other authors have no sources of funding to acknowledge.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank obtained ethical approval for this study by the North West Multicenter Research Ethics Committee and all participants gave written informed consent to participate and be followed up. All additional participants from the Geisinger Health System MyCode Community Health Initiative, University of Pennsylvania Penn Medicine BioBank, and AncestryDNA customers provided informed consent to participate in research under IRB-approved protocols at each institution. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genotype-phenotype association results reported in this study are available for browsing using the RGC COVID-19 Results Browser (https://rgc-covid19.regeneron.com). Data access and use is limited to research purposes in accordance with the Terms of Use (https://rgc-covid19.regeneron.com/terms-of-use). https://rgc-covid19.regeneron.com